Gara Jalqabaatti › Myelofibrosis › Texas › Houston
Qorannoo klinikaalii Myelofibrosis Houston, TX keessatti
Qorannoo 19 Myelofibrosis f Houston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Namoota walitti qabaa jiraSadarkaa 3
- MD Anderson Cancer Center, Houston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Namoota walitti qabaa jiraSadarkaa 3
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- LUMI Research, Houston
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas, MD Anderson Cancer Center, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson, Houston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Namoota walitti qabaa jiraSadarkaa 1
- University of Texas M. D. Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Namoota walitti qabaa jiraSadarkaa 2
- GSK Investigational Site, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Namoota walitti qabaa jiraSadarkaa 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson, Houston
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Namoota walitti qabaa jiraSadarkaa 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Houston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Namoota walitti qabaa jiraSadarkaa 3
- U.T. MD Anderson Cancer Center, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Namoota walitti qabaa jiraSadarkaa 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Qorannoo Myelofibrosis magaalota biroo keessatti
- New York City, NYQorannoo 18
- Boston, MAQorannoo 12
- Durham, NCQorannoo 12
- Columbus, OHQorannoo 11
- Seattle, WAQorannoo 11
- Salt Lake City, UTQorannoo 10
- Miami, FLQorannoo 10
- Atlanta, GAQorannoo 9
- Baldwin Park, CAQorannoo 9
- Nashville, TNQorannoo 9
- Tampa, FLQorannoo 9
- Cleveland, OHQorannoo 9
Qorannoo biroo Houston keessatti
- Kansara Qara'a Non-Small CellQorannoo 145
- Saree OljooQorannoo 126
- Saree (Gosoota Hunda)Qorannoo 121
- Kansara MetastatikiiQorannoo 104
- Kansarii ColorectalQorannoo 102
- Kansarii OvariiQorannoo 89
- Leukemia Myeloidii HamaaQorannoo 85
- Dhibee QaraQorannoo 78
- Kansarii ProstateQorannoo 76
- Kansa EndometiriyaaliiQorannoo 68
- Kansarii PancreasQorannoo 61
- MelanomaQorannoo 59
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.